Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

Alkermes plc diskutieren

Alkermes plc

WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

22,60 €
0,89 %

Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for ALKS provided by MarketBeat

Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for ALKS provided by MarketBeat

Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.
Ratings data for ALKS provided by MarketBeat

Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for ALKS provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 33,13
Veränderung
Endet am 26.10.24

Alkermes plc (NASDAQ: ALKS) had its price target lowered by analysts at Mizuho from $37.00 to $35.00. They now have a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 33,15
Veränderung
Endet am 27.10.24

Alkermes plc (NASDAQ: ALKS) had its price target lowered by analysts at Piper Sandler from $37.00 to $35.00. They now have an "overweight" rating on the stock.
Ratings data for ALKS provided by MarketBeat

Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for ALKS provided by MarketBeat

Alkermes plc (NASDAQ: ALKS) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat

Alkermes plc (NASDAQ: ALKS) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat

Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for ALKS provided by MarketBeat

Einschätzung Buy
Rendite (%) -23,49 %
Kursziel 36,20
Veränderung
Endet am 16.02.25

Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Piper Sandler from $35.00 to $39.00. They now have an "overweight" rating on the stock.
Ratings data for ALKS provided by MarketBeat

Einschätzung Sell
Rendite (%) -18,57 %
Kursziel 23,09
Veränderung
Endet am 20.02.25

Alkermes plc (NASDAQ: ALKS) was downgraded by analysts at UBS Group AG from a "neutral" rating to a "sell" rating. They now have a $25.00 price target on the stock.
Ratings data for ALKS provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,24 %
Kursziel 34,08
Veränderung
Endet am 19.03.25

Alkermes plc (NASDAQ: ALKS) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $37.00 price target on the stock.
Ratings data for ALKS provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,94 %
Kursziel 36,29
Veränderung
Endet am 01.04.25

Alkermes plc (NASDAQ: ALKS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $39.00 price target on the stock.
Ratings data for ALKS provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,06 %
Kursziel 46,03
Veränderung
Endet am 09.04.25

Alkermes plc (NASDAQ: ALKS) had its price target raised by analysts at Jefferies Financial Group Inc. from $42.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for ALKS provided by MarketBeat